RHUMBLINE ADVISERS

Position in ZYME — Zymeworks Inc.

CIK 1115418 BOSTON, MA

Position in ZYME

as of Jun 30, 2026 · filed Aug 12, 2026 Compact

Position Value

$1,962,225

+$74,235 QoQ

Shares Held

75,066

-0.4% QoQ

Ownership

0.106%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#67

of 202 holders

Holding Since

Jun 2023

13 quarters on record

Voting authority Sole 34% Shared 0% None 66%

Healthcare · as of Jun 30, 2026

RHUMBLINE ADVISERS holds $1,414,750,230 across 329 Biotechnology names. ZYME ranks #100 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	396,380	$196,893,837
2	REGN	Regeneron Pharmaceuticals, Inc.	157,794	$98,390,870
3	MRNA	Moderna, Inc.	809,853	$56,714,005
4	ALNY	Alnylam Pharmaceuticals, Inc.	165,579	$49,844,246
5	INCY	Incyte Corp	428,533	$48,578,500
6	RVMD	Revolution Medicines, Inc.	226,008	$42,326,778
7	ROIV	Roivant Sciences Ltd.	1,178,789	$41,717,342
8	JAZZ	Jazz Pharmaceuticals plc	163,018	$39,282,447

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$1,962,225	75,066	-0.4%	Shares	Sole	2026-08-12
2026-03-31	$1,887,990	75,399	-0.1%	Shares	Sole	2026-05-12
2025-12-31	$1,987,862	75,498	-12.1%	Shares	Sole	2026-02-13
2025-09-30	$1,467,206	85,902	-0.2%	Shares	Sole	2025-11-06
2025-06-30	$1,080,341	86,083	+4.0%	Shares	Sole	2025-08-12
2025-03-31	$985,409	82,738	-20.3%	Shares	Sole	2025-05-29
2024-12-31	$1,520,744	103,876	+18.1%	Shares	Sole	2025-05-29
2024-09-30	$1,103,847	87,956	+1.2%	Shares	Sole	2024-11-12
2024-06-30	$739,621	86,912	+9.0%	Shares	Sole	2024-08-01
2024-03-31	$838,465	79,702	+2.7%	Shares	Sole	2024-05-09
2023-12-31	$806,232	77,597	+7.6%	Shares	Sole	2024-02-08
2023-09-30	$457,158	72,107	+3.0%	Shares	Sole	2023-11-09
2023-06-30	$604,920	70,014	—	Shares	Sole	2023-08-08
No filing history on record for this holder in this stock.